Elevated Creatinine and AKI Are NOT Synonymous: Optimal RAASi Therapy Is Always the Goal

Elevated Creatinine and AKI Are NOT Synonymous: Optimal RAASi Therapy Is Always the Goal

Elevated Creatinine and AKI Are NOT Synonymous: Optimal RAASi Therapy Is Always the Goal

What are the benefits of continuing RAASi therapy when treating patients with heart failure and CKD? What about hyperkalemia? Tune in for answers.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    When treating patients with heart failure and chronic kidney disease, RAASi therapy should be continued if at all possible. One thing to keep in mind is that an elevation in serum creatinine does not always represent acute kidney injury. In this activity, Drs. George Bakris, Biykem Bozkurt, and Robert Toto examine a case study and discuss transient changes in serum creatinine with hyperkalemia. Join us to find out how and why you should avoid RAAS blockade interruption in these patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    George L. Bakris, MD
    Professor of Medicine
    Director, Am Heart Assoc. Comprehensive Hypertension Center
    University of Chicago Medicine
    Chicago, IL

    Consulting Fees: Alnylam, Ionis, Merck, Relypsa

    Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
    Director, Winters Center for Heart Failure Research
    Assoc. Director, Cardiovascular Research Institute
    Vice-Chair of Medicine, Baylor College of Medicine
    Houston, TX 

    Biykem Bozkurt has nothing to disclose.

    Robert Toto, MD
    Associate Dean, Translational Science
    UT Southwestern Medical Center
    Dallas, TX 

    Consulting Fees: AstraZeneca, ACI, Boehringer-Ingelheim, Bayer, Medscape, Reata, Vifor Pharma

    Reviewers/Content Planners/Authors:

    • Nancy Ashley, MSN, APRN, ANP-BC, CCRN, CEN, has nothing to disclose.
    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Define the benefits of RAASi therapy in patients with HTN, CKD, and HF and the importance of not interrupting therapy
    • Examine transient changes in serum creatinine and eGFR suspicious for AKI and the impact on continued RAASi therapy and management of hyperkalemia
    • Discuss ways to help minimize interruption of RAASi therapy with potassium binders in the presence of hyperkalemia and suggested parameters for lab value concerns
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, nephrologists, primary care physicians, and all allied healthcare professionals involved in the diagnosis and treatment of HF and CKD.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free